全文获取类型
收费全文 | 548篇 |
免费 | 54篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 4篇 |
妇产科学 | 3篇 |
基础医学 | 61篇 |
口腔科学 | 3篇 |
临床医学 | 44篇 |
内科学 | 305篇 |
神经病学 | 1篇 |
特种医学 | 4篇 |
外科学 | 12篇 |
综合类 | 2篇 |
预防医学 | 28篇 |
眼科学 | 4篇 |
药学 | 7篇 |
肿瘤学 | 107篇 |
出版年
2023年 | 4篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 21篇 |
2010年 | 7篇 |
2009年 | 6篇 |
2008年 | 14篇 |
2007年 | 29篇 |
2006年 | 27篇 |
2005年 | 21篇 |
2004年 | 42篇 |
2003年 | 25篇 |
2002年 | 31篇 |
2001年 | 30篇 |
2000年 | 33篇 |
1999年 | 25篇 |
1998年 | 6篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 3篇 |
1994年 | 10篇 |
1993年 | 3篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 17篇 |
1989年 | 15篇 |
1988年 | 10篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 7篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1968年 | 1篇 |
1940年 | 2篇 |
1928年 | 1篇 |
排序方式: 共有602条查询结果,搜索用时 15 毫秒
41.
42.
L Champlin 《The American nurse》1989,21(9):suppl 2, 8-suppl 2, 9
43.
44.
45.
46.
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy 总被引:30,自引:48,他引:30
Giralt Sergio; Estey Elihu; Albitar Maher; van Besien Koen; Rondon Gabriela; Anderlini Paolo; O'Brien Susan; Khouri Issa; Gajewski James; Mehra Rakesh; Claxton David; Andersson Borje; Beran Miloslav; Przepiorka Donna; Koller Charles; Kornblau Steve; Korbling Martin; Keating Michael; Kantarjian Hagop; Champlin Richard 《Blood》1997,89(12):4531-4536
47.
Gurkan E Patah PA Saliba RM Ramos CA Anderson BS Champlin R de Lima M Lichtiger B 《Bone marrow transplantation》2007,40(5):461-464
Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions administered to 33 patients with AML/MDS during the first 100 days after busulfan-based, myeloablative HSCT. All donor-recipient pairs were ABO identical. Transfusion threshold was a platelet count < or =15 x 10(9)/l. The corrected increment (CCI) was used for all comparisons. Median time to platelet engraftment was 13 days (n=30). PPC transfusions (n=105) were ABO compatible, while 10% of 41 SDAP were not (P=0.006). Median post-transfusion platelet count was 51K/microl (5-118K) after SDAP and 36K/microl (3-115K) after PPC (P=0.0004). Median CCI was 14.178 (SDAP) versus 7.793 (PPC) (P=0.0001). Median time to another transfusion was 3 days (SDAP) and 2 days (PPC; P=0.3). In the week following any given transfusion, the median number of new transfusions was similar (n=2), as well as the need of further transfusion (16 versus 24%, P=0.2). A total of 17% of SDAP and 30% of PPC transfusions were labeled 'ineffective' (P=0.1). There were two non-lethal hemorrhage episodes (6%). SDAP transfusions produced better platelet counts, but SDAP and PPC were equally effective in preventing hemorrhage. 相似文献
48.
Safdar A Rodriguez G Rolston KV O'Brien S Khouri IF Shpall EJ Keating MJ Kantarjian HM Champlin RE Raad II Kontoyiannis DP 《Bone marrow transplantation》2007,39(3):157-164
Pneumocandins have concentration-dependent antifungal activity and higher dose of caspofungin (HD-CAP) in combination with other licensed antifungal therapy (OLAT) may improve response. Thirty-four patients who received HD-CAP were compared with 63 patients who received standard dose (SD)-CAP. There were no differences between the groups in either patient or disease characteristics. Significantly more patients in the HD-CAP arm had extrapulmonary infections (29 vs 8% in SD group; P=0.0053), and non-Aspergillus species infection (21 vs 6%; P=0.05) and had received prior antifungal therapy (71 vs 33%; P=0.0004). No serious adverse reactions were noted in patients receiving HD- or SD-CAP therapy. Twelve weeks after treatment commenced 44% had a complete or partial response compared with 29% in SD-CAP group (P=0.1). Logistic regression analysis showed a significant probability of a favorable outcome at 12 weeks in patients who received HD-CAP (OR 3.066, 95% CI, 1.092-8.61; P=0.033). This may in part reflect higher number of patients in HD group had received granulocyte-macrophage colony-stimulating factor (41 vs 14% in SD group; P=0.04) and/or interferon gamma (26 vs 5% in SD group; P=0.003) immune enhancement. Further studies are needed to evaluate efficacy of HD-CAP in severely immunosuppressed cancer patients with invasive fungal infections. 相似文献
49.
Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Champlin RE Perez WS Passweg JR Klein JP Camitta BM Gluckman E Bredeson CN Eapen M Horowitz MM 《Blood》2007,109(10):4582-4585
The addition of antithymocyte globulin (ATG) to a regimen of high-dose cyclophosphamide has been advocated to enhance engraftment after allogeneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA). In a prospective clinical trial, 134 patients were randomly assigned to receive cyclophosphamide alone or in combination with ATG. All patients received T-cellreplete bone marrow from an HLA-matched sibling. With a median follow-up of 6 years, the 5-year probabilities of survival were 74% for the cyclophosphamide alone group and 80% for the cyclophosphamide plus ATG group (P = .44). Graft failure and graft-versus-host disease (GVHD) rates were similar in both groups. With the survival rates achieved, this study is not adequately powered to detect significant differences between the 2 treatment groups. In conclusion, the results of allogeneic BMT for SAA have improved over time related to advances in supportive care. The addition of ATG to the preparative regimen did not significantly improve the outcome. 相似文献
50.
Oren Pasvolsky Curtis Marcoux Denái R. Milton Mark R. Tanner Qaiser Bashir Samer Srour Neeraj Saini Paul Lin Jeremy Ramdial Yago Nieto Hans C. Lee Krina K. Patel Partow Kebriaei Priti Tewari Lindsay Crawford-Suber Sheeba K. Thomas Donna M. Weber Robert Z. Orlowski Elizabeth J. Shpall Richard E. Champlin Muzaffar H. Qazilbash 《British journal of haematology》2023,202(4):866-873
Multiple myeloma (MM) primarily affects older patients. There are scarce data on the outcomes of young adults undergoing autologous transplantation (auto-HCT). In this single-centre analysis, we included 117 younger patients, with a median age of 37 years (range 22–40) at transplant. Seventeen (15%) patients had high-risk cytogenetics. Before transplant, 10% of patients achieved ≥CR and 44% achieved ≥VGPR. At best post-transplant response, 56% and 77% of patients achieved ≥CR and ≥VGPR respectively. With a median follow-up for survivors of 72.6 months (range 0.9–238.0), median PFS and OS were 43.1 months (95% CI 31.2–65.0) and 146.6 months (95% CI 100.0–208.1) respectively. Patients who underwent auto-HCT after 2010 had better median PFS (84.9 months vs. 28.2 months, p < 0.001) and OS (NR vs. 91.8 months, p < 0.001) compared with those transplanted earlier. In multi-variate analysis, achieving ≥CR as best post-transplant response was associated with improved PFS (HR [95% CI] 0.55 [0.32–0.95], p = 0.032), while achieving ≥VGPR was predictive of superior OS (0.32 [0.16–0.62], p < 0.001). Three patients (3%) developed a second primary malignancy. Younger MM patients had durable survival after auto-HCT, which further improved after the availability of novel anti-myeloma drugs in recent years. Depth of response following transplant remains a key predictor of survival. 相似文献